Portola Pharmaceuticals (PTLA) Given Daily News Impact Rating of 0.11
Headlines about Portola Pharmaceuticals (NASDAQ:PTLA) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.1212960593139 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Hot Pharma stock to watch: Portola Pharmaceuticals Inc(NASDAQ: PTLA) (fxdailyreport.com)
- $2.42 Million in Sales Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter (americanbankingnews.com)
- Portola Pharma (PTLA) to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at ASH (streetinsider.com)
- Portola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting (finance.yahoo.com)
- Zacks: Analysts Expect Portola Pharmaceuticals Inc (PTLA) to Post -$1.52 EPS (americanbankingnews.com)
A number of research analysts have recently weighed in on the company. Zacks Investment Research downgraded Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Credit Suisse Group set a $70.00 price target on Portola Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, August 10th. They noted that the move was a valuation call. Oppenheimer reiterated a “buy” rating and set a $80.00 price target on shares of Portola Pharmaceuticals in a report on Wednesday, September 6th. BidaskClub upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $81.00 price target (up previously from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $71.15.
Shares of Portola Pharmaceuticals (PTLA) traded up $3.18 during mid-day trading on Friday, hitting $53.93. The stock had a trading volume of 1,398,102 shares, compared to its average volume of 641,368. Portola Pharmaceuticals has a twelve month low of $17.15 and a twelve month high of $67.10. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.71 million. During the same quarter in the previous year, the company posted ($1.64) earnings per share. Portola Pharmaceuticals’s revenue for the quarter was down 58.9% compared to the same quarter last year. equities research analysts anticipate that Portola Pharmaceuticals will post -4.95 EPS for the current year.
WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/portola-pharmaceuticals-ptla-given-daily-news-impact-rating-of-0-11/1742029.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.